Stellaromics today launched Pyxa™, the first commercially available platform to deliver multiplexed 3D spatial transcriptomics in intact tissue up to 100 micrometers thick. The launch marks a ...
Advances in 3D spatial multiomics are changing how researchers study tissue architecture. We spoke with Stellaromics' CEO, Dr. Todd Dickinson, to learn how this approach preserves structure and ...
Dr. Hailing Shi to apply 3D spatial multi-omics to decode RNA regulation in the human brain and neurodegenerative diseases BOSTON, Jan. 28, 2026 /PRNewswire/ -- Stellaromics, a pioneer in ...
Renowned vision researcher Dr. Rui Chen to apply 3D spatial multi-omics for mapping sensory systems and advancing Human Cell Atlas discoveries BOSTON, Dec. 3, 2025 /PRNewswire/ -- Stellaromics, a ...
Researchers launched external beta testing of a 3D spatial transcriptomics system that maps intact tumors in three dimensions and enabling single-cell resolution.
BOSTON, Oct. 14, 2025 /PRNewswire/ -- Stellaromics, a pioneer in 3D spatial biology, today announces the installation of the first Pyxa™ instrument at the University of Glasgow in the laboratory of Dr ...
A new software tool, ovrlpy, improves quality control in spatial transcriptomics, a key technology in biomedical research. Developed by the Berlin Institute of Health at Charité (BIH) in international ...
Conventional transcriptomic techniques have revealed much about gene expression at the population and single-cell level—but they overlook one crucial factor: spatial context. In musculoskeletal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results